Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHG-31
- Development stage
- Preclinical
- Lead developer
- University of Hertfordshire
- Modality
- Small Molecules
01
Overview
SHG-31 is a synthetic dibenzalacetone derivative compound being developed by researchers at the University of Hertfordshire as a potential therapeutic agent for glioblastoma. In preclinical in vitro studies using glioblastoma cell lines (A172 and U87MG), SHG-31 demonstrated significant anti-cancer properties, including the induction of cell death, inhibition of cell proliferation and colony formation, and delay of tumor cell migration. Mechanistically, SHG-31 treatment has been shown to induce apoptosis, which is associated with the upregulation of apoptotic genes such as BAX and CASP3 (Caspase-3).
- Other names
- SHG31SHG-31SHG 31
Beyond the preview
Go deeper on SHG-31.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHG-31.